These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 24667275)

  • 1. A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy.
    Chebli JM; Gaburri PD; Chebli LA; da Rocha Ribeiro TC; Pinto AL; Ambrogini Júnior O; Damião AO
    Med Sci Monit; 2014 Mar; 20():487-98. PubMed ID: 24667275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment.
    Nordgaard-Lassen I; Dahlerup JF; Belard E; Gerstoft J; Kjeldsen J; Kragballe K; Ravn P; Sørensen IJ; Theede K; Tjellesen L;
    Dan Med J; 2012 Jul; 59(7):C4480. PubMed ID: 22759856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients.
    Abreu C; Sarmento A; Magro F
    Dig Liver Dis; 2017 Dec; 49(12):1289-1297. PubMed ID: 28986117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
    Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy.
    Vaughn BP; Doherty GA; Gautam S; Moss AC; Cheifetz AS
    Inflamm Bowel Dis; 2012 Jun; 18(6):1057-63. PubMed ID: 21953829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia.
    Connell W; Andrews JM; Brown S; Sparrow M
    Intern Med J; 2010 Feb; 40(2):139-49. PubMed ID: 20446955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B Virus Screening and Reactivation in a National VA Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Antagonists.
    Shah R; Ho EY; Kramer JR; Richardson P; Sansgiry S; El-Serag HB; Hou JK
    Dig Dis Sci; 2018 Jun; 63(6):1551-1557. PubMed ID: 29663266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of surveillance of hepatitis b and hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3).
    Loras C; Gisbert JP; Saro MC; Piqueras M; Sánchez-Montes C; Barrio J; Ordás I; Montserrat A; Ferreiro R; Zabana Y; Chaparro M; Fernández-Bañares F; Esteve M;
    J Crohns Colitis; 2014 Nov; 8(11):1529-38. PubMed ID: 25052345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
    Peter I; Dubinsky M; Bressman S; Park A; Lu C; Chen N; Wang A
    JAMA Neurol; 2018 Aug; 75(8):939-946. PubMed ID: 29710331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.
    Papa A; Felice C; Marzo M; Andrisani G; Armuzzi A; Covino M; Mocci G; Pugliese D; De Vitis I; Gasbarrini A; Rapaccini GL; Guidi L
    J Crohns Colitis; 2013 Mar; 7(2):113-9. PubMed ID: 22464811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of infections in patients with inflammatory bowel disease during TNF inhibitor treatment].
    Christensen KR; Steenholdt C
    Ugeskr Laeger; 2014 Nov; 176(48):. PubMed ID: 25430572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management.
    Lee J; Clarke K
    Int J Colorectal Dis; 2015 Dec; 30(12):1595-602. PubMed ID: 26349591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.
    Lin MV; Blonski W; Buchner AM; Reddy KR; Lichtenstein GR
    Dig Dis Sci; 2013 Apr; 58(4):1149-56. PubMed ID: 23179145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
    Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
    Porcari S; Viola A; Orlando A; Privitera AC; Ferracane C; Cappello M; Vitello A; Siringo S; Inserra G; Magnano A; Mocciaro F; Di Mitri R; Belluardo N; Fidanza O; Garufi S; Magrì G; Bertolami C; Carroccio A; Macaluso FS; Renna S; Ventimiglia M; Alibrandi A; Cottone M; Fries W;
    Drugs Aging; 2020 May; 37(5):383-392. PubMed ID: 32016824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Lichen Planus in IBD Patients: A Paradoxical Adverse Effect of Anti-TNF-α Therapy.
    Andrade P; Lopes S; Albuquerque A; Osório F; Pardal J; Macedo G
    Dig Dis Sci; 2015 Sep; 60(9):2746-9. PubMed ID: 25917051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.